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Human papillomavirus (HPV)is the most commonnewly diagnosed sexually transmittedinfection inthe United States. Although
the majority of sexually active adults will be infected with HPV at least once in their lives, it is sexually active women less than
25 years of age who consistently have the highest rates of infection. Besides youth and gender, common risk factors for HPV
infection and clinical sequelae of infection include high number of sexual partners and coinfection with Chlamydia trachomatis or
herpes simplex virus. Most HPV infections are cleared by the immune system and do not result in clinical complications. Clinical
sequelae in cases of low-risk HPV infection consist of genital warts, and clinical manifestations of high-risk HPV infection include
abnormal Pap test results, low-grade squamous intraepithelial lesions (LSIL), high-grade squamous intraepithelial lesions (HSIL),
and cervical cancer. LSIL, HSIL, and cervical cancer carry signiﬁcant morbidity and/or mortality; genital warts and abnormal Pap
test results are often signiﬁcant sources of psychosocial distress. Currently, there are neither eﬀective means of preventing HPV
transmission nor cures for clinical manifestations: infection can only be prevented via complete sexual abstinence, while treatment
for clinical sequelae such as genital warts and cytologic abnormalities consists of removing the problematic cells and watching
for recurrence; this method consumes signiﬁcant health care resources and is costly. New prophylactic HPV vaccines promise to
dramatically reduce the incidence of HPV infection, genital warts, and cytologic abnormalities.
Copyright © 2006 Kevin A. Ault.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
Human papillomavirus (HPV) is a signiﬁcant source of
morbidity and mortality in the United States and worldwide.
High-risk, oncogenic HPV types (including HPV 16 and
HPV 18) are associated with 99.7% of all cervical cancers,
as well as low-grade squamous intraepithelial lesions (LSIL),
high-grade squamous intraepithelial lesions (HSIL), and ab-
normal Papanicolaou (Pap) test results, which carry signiﬁ-
cant health care costs and psychosocial morbidity. Low-risk
HPV types (HPV 6 and HPV 11) are responsible for addi-
tional abnormal Pap test results, as well as almost all cases
of genital warts. HPV is so common that more than half of
all sexually active adults will be infected in their lifetime, al-
though young, sexually active women bear the brunt of both
infection and clinical complications. Currently there are nei-
ther eﬀective HPV prevention strategies nor good treatments
for individuals with genital warts or cervical lesions; avail-
able treatments focus on removing the aﬀected area, and re-
currenceiscommon.Prophylacticvaccineswillsoonbecome
available, and promise to signiﬁcantly reduce the morbidity
and mortality associated with these infections.
EPIDEMIOLOGY OF HUMAN PAPILLOMAVIRUS
INFECTIONS
Approximately 6.2 million new HPV infections occur every
year in the United States, and approximately 20 million in-
dividuals are currently infected [1]. HPV is spread by skin-
to-skin sexual contact and is prevalent in all sexually active
populations. The Centers for Disease Control estimates that
at least half of all sexually active individuals will acquire HPV
at some point in their lives, whereas at least 80% of women
will acquire an HPV infection by age 50 [1]. In the United
States, it is estimated that 10% of the population has an ac-
tive HPV infection, 4% has an infection that has caused cy-
tological abnormalities, and an additional 1% have infection
causing genital warts [2]. Although 1% of Americans have
clinically visible genital warts, as many as 13% of those at-
tending STD clinics have genital warts [2]. The greatest risk
factors for infection are gender, youth, and sexual activity,
with the highest rates being consistently found in sexually
active women less than 25 years of age. Winer et al followed
148 female university students as they initiated sexual activ-
ity(Figure 1)[3].TheyfoundacumulativeincidenceofHPV2 Infectious Diseases in Obstetrics and Gynecology
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Figure 1: Cumulative rate of HPV infection among college-aged
women who were virgins at baseline. Adapted from Winer et al [3].
of 38.9% at 24 months. HPV 16 was the most common type,
with a cumulative infection rate of 10.4% at 24 months; the
cumulative incidence of HPV 18 infection was 4.1% for the
same time period. Brown et al studied a smaller cohort of
mid-adolescent women for two years. Of the women stud-
ied, 82% were infected with HPV during the 2-year study pe-
riod [4]. DNA from both low-risk and high-risk HPV types
has even been found in women who have sex with women,
a population that would be expected to have a low incidence
of HPV infection [5]. It should be noted that prevalence es-
timates vary depending on the technique used to assess viral
load; polymerase chain reaction analysis is a more sensitive
detection method and yields higher rates of prevalence.
HPV 16 alone is linked to more than 50% of all cervical
cancers[6];thus,theprevalenceofHPV16isofspecialinter-
est. One study utilized an experimental serological test to de-
termine the presence of antibodies to HPV 16, which signify
prior exposure to HPV, instead of the more commonly as-
sessedviralDNAwhichisindicativeofactiveinfection.More
than 7000 sera were tested from a national sample from the
United States. Gender and age speciﬁc ﬁndings are shown in
Figure 2.WomenweremorelikelytobeseropositiveforHPV
16 (17.9%) than were men (7.9%). However, this method-
ology may in fact underestimate the true prior exposure to
HPV 16, because <60% of women infected with HPV 16 de-
velop type-speciﬁc antibodies [6].
Sexual activity is the primary risk factor for HPV in-
fection, but condoms, although eﬀective at preventing the
spread of many other sexually transmitted infections, may
notpreventallHPVinfections.Ameta-analysisofmorethan
20 trials investigating the role of condoms in HPV trans-
mission and the development of clinical complications con-
cluded that, although condoms do not protect against cervi-
cal infection, they may oﬀer some protection against HPV-
associated disease. Speciﬁcally, although there is conﬂicting
evidence as to whether condom use protects against CIN 2/3,
condoms may protect against cervical cancer [7]. A recent
prospective study by Hogewoning et al studied the eﬀect of
condom use on the regression of CIN lesions. Women with
abnormal cervical smears or CIN were randomized to use
condoms after the initial diagnosis. The 2-year cumulative
regression rate was 53% in the “condom” group and 35%
in the “noncondom” group. The 2-year cumulative rate of
HPV clearance was 23% in the condom group and 4% in the
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Figure 2: Seroprevalence of HPV 16 by age and gender. Modiﬁed
from Stone et al [6].
noncondom group [8]. It is diﬃcult to accurately assess the
role of condoms in preventing HPV infection and the devel-
opment of clinical complications of infections, not least be-
cause investigators rely on patient self-report to assess con-
dom use. The available evidence does, however, suggest that
condom use protects against some clinical sequelae of HPV
infection and aids clearance of infection and clinical symp-
t o m s ,e v e ni fi td o e sn o tp r e v e n tp r i m a r yi n f e c t i o n .
NATURAL HISTORY OF HPV INFECTION
HPV is a small DNA virus with a genome of approximately
8000 base pairs [9]. HPV targets the basal cells in the strat-
iﬁed squamous epithelium and the metaplastic cells at the
squamocolumnar junction of the cervix. Additionally, HPV
may infect the glandular epithelium of the endocervix, re-
sulting in glandular neoplasms, such as adenocarcinoma
in situ or invasive adenocarcinoma [10]. The two primary
oncogenes of high-risk HPV types are E6 and E7. The “E”
designation indicates that these two genes are expressed early
in the HPV life cycle. The products of these two genes al-
ter host-cell metabolism to favor neoplastic development. E6
binds to and degrades the host-cell protein p53. An eﬀect of
this targeted degradation is to prevent apoptosis of the in-
fected host epithelial cells. Telomerase is also activated, fur-
ther augmenting oncogenic changes. The E7 protein has a
similar eﬀect on cell metabolism by binding to retinoblas-
toma protein, inhibiting its function. This leads to disrup-
tion of the cell cycle [9]. In addition, E6 and E7 proteins
may cause chromosomal destabilization, and inhibit cyclin-
dependent kinase inhibitors and host interferons [11].
The degree of expression of HPV E6 and E7 is highly cor-
related with the type of cervical lesion: in low-grade lesions,
E6 and E7 are expressed at low levels in the basal cells and
higher levels in the upper layers of the epithelium, whereas
in high-grade lesions E6 and E7 are expressed at high levels
throughout the epithelium [9]. In low-grade lesions, HPV is
inepisomalform,whereasinhighergradelesionsandcancer,
the HPV DNA is more likely to have been integrated into the
host-cell chromosome. The integration of HPV DNA into
the host DNA increases cellular proliferation and the chance
of malignancy [9].Kevin A. Ault 3
HPV infection, unlike many genitourinary infections, is
not usually associated with immediate symptoms such as
itching, burning, and vaginal discharge [12]. Rather, the ma-
jority of those infected with HPV will not develop clinical
disease or symptoms because the host immune system re-
solves most infections. In one study, only 24.8% of women
infected with HPV 6 or 11 actually developed genital warts
[12]. A large, prospective 10-year cohort study of more than
20,000womenenrolledinahealthmaintenanceorganization
found that the incidence of CIN 3 or cancer was approxi-
mately 7% in HPV-positive women for the duration of the
study [13]. Thus, only the minority of patients with HPV
infections develop serious clinical complications. The exact
mechanism by which HPV infection is cleared by the host
immune system is currently unknown.
A number of factors are associated with an increased risk
of initial infection and/or clinical sequelae such as genital
warts, CIN or invasive cancer. Individuals who smoke are
more likely to develop cancer, and it is thought that smok-
ing increases the likelihood of developing SIL [14]. Herpes
simplex virus (HSV) and C. trachomatis infection are also as-
sociated with cervical cancer. Smith et al performed a pooled
analysis that found prior exposure to HSV-2 was associated
with 2-fold increased risk of squamous cell carcinoma of the
cervix in patients with HPV [15]; C. trachomatis infection is
associated with a similarly increased risk of squamous cell
carcinoma [16]. C. trachomatis infection is also associated
with more persistent HPV infection, which may contribute
to the increased risk of clinical complications of HPV infec-
tion in individuals coinfected with C. trachomatis [17].
Immunosuppressed and HIV positive individuals are at
a high risk of both HPV infection and HPV-associated dis-
ease. High HIV RNA levels and CD4 < 200 cells per mm3
counts are associated with both incident and persistent HPV
infection, although the association with incident infection is
stronger [18]. Among women with oncogenic HPV, HIV-
positive women with low CD4 cell counts are more likely
than either HIV-negative women or HIV-positive women
with high CD4 cell counts to develop SIL [19]. Data con-
cerning the eﬀect of highly active anti-retroviral therapy on
the natural history of HPV infections and cervical dysplasia
are mixed and further investigation is needed in this area.
HPV INFECTION AND CERVICAL CANCER
Steps that occur from initial infection leading to the develop-
ment of cancer include overcoming host immune resistance,
possible integration of HPV DNA into the host genome, and
accumulation of additional mutations within the infected
host cell [11]. HPV must be persistent within the host ep-
ithelialcellsasapreliminarysteptowardadvancedneoplastic
changes. The traditional view has been that this process takes
years, if not decades, to occur after initial HPV infection. Re-
cent studies suggest that these changes may develop more
quicklythanpreviouslythought.Wineretalfollowedwomen
after initial HPV infection for the development of CIN 2/3.
As shown in Figure 3, approximately 27% of women with an
initial HPV 16 or 18 infection progressed to CIN 2/3 within
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Figure 3: Cumulative risk of CIN 2/3 after infection with HPV 16
or 18, or other types. Adapted from Winer et al [20].
36 months [20]. A second study of a large health mainte-
nance cohort found that approximately 20% of women 30
years of age or older who were initially infected with HPV
16 developed CIN 3 or cervical cancer within 120 months.
Women who had an initial HPV 18 infection had approxi-
mately a 15% risk of developing CIN 3 or cervical cancer at
120 months [21].
The strong correlation between infection with high-risk
types of HPV and LSIL, HSIL, and cervical cancer suggests
that HPV DNA testing would be a useful tool for the man-
agement of women with abnormal Pap test results, especially
in the case of those with equivocal test results. In the case
of an equivocal Pap test result, HPV DNA testing can help
determine whether the individual should be referred for col-
poscopic assessment [22].
COSTS OF INFECTION
HPV is one of the most common infections of the female
genital tract, and it is also one of the most costly. HPV-
associated health care costs include routine Pap tests, treat-
ment of genital warts, follow-up of cytological abnormali-
ties, and management of cervical malignancies. An observa-
tional study of the Kaiser Permanente health plan found that
the annual cost of screening and treatment of HPV-related
cervical neoplasia was $26,415 per 1000 women, with nearly
2/3 of that ($16,746) attributable to routine screening [23].
Another large study investigated the incidence and costs as-
sociated with genital warts: each episode of genital warts re-
quired an average of 3.1 doctor visits, with an average total
cost of $436 for all visits. Incidence ranged from 1.7 cases
per 1000 patient-years overall to a peak of 6.2 cases of genital
warts per 1000 person-years, in women aged 20 to 24 years,
atacostof$1692per1000person-years,and5casesper1000
patient-yearsinmenaged25to29atacostof$1717per1000
patient-years [24].
CurrentlytherearenogoodmethodsforpreventingHPV
infection. Nor are there comprehensive and eﬀective treat-
ments for the clinical consequences of infection: for both
genital warts and lesions, management entails removal of
discrete lesions and monitoring for recurrence. Prophylac-
tic HPV vaccines that confer protection against both high-
and low-risk HPV types are expected to substantially reduce
the burden of HPV-associated disease. A bivalent vaccine4 Infectious Diseases in Obstetrics and Gynecology
formulated to protect against the two most common high-
risk HPV types, 16 and 18, and a quadrivalent vaccine that
will protect against HPV 16 and 18, and the two most com-
mon low-risk types, HPV 6 and 11, are in ongoing clinical
testing. Phase 2 data suggest that both vaccines are safe, are
capable of producing immune responses in orders of mag-
nitude larger than those produced in the wake of a natu-
ral infection, and are more than 90% eﬀective at preventing
persistent HPV infection and the clinical manifestations of
HPVinfection;recentphase3datasuggestthatthequadriva-
lent vaccine may be 100% eﬀective at preventing HPV 16/18-
associated disease [25–27].
CONCLUSION
The vast majority of sexually active men and women will be-
come infected with HPV. Although the host immune system
successfully clears most of these infections, some women will
develop fulminant disease such as genital warts, cervical dys-
plasia, and invasive cervical cancer. Current treatment op-
tions are not curative; therefore, preventative vaccines that
lower the incidence of HPV infection and its associated dis-
eases may oﬀer a promising alternative to current therapies.
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